Pharmacoeconomics of antipsychotic drug therapy

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 9, 1996, Pages 66-76

  Hargreaves, William A ^a,b   Shumway, Martha ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SFGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; RISPERIDONE;

CONFERENCE PAPER; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; PHARMACOECONOMICS; PRIORITY JOURNAL; PSYCHOSIS;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; CLOZAPINE; COST-BENEFIT ANALYSIS; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; HUMANS; PATIENT SELECTION; PSYCHOTIC DISORDERS; RESEARCH DESIGN; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA;

EID: 0029816491     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (47)

1. Revicki DA, Luce BR. Pharmacoeconomics research applied to psychopharmacology development and evaluation. Psychopharmacol Bull 1995; 31:45-53
2. Terkelsen KG, Grosser RC. Estimating clozapine's cost to the nation. Hosp Community Psychiatry 1990;41:863-869
3. Juarez-Reyes M, Shumway M, Battle C, et al. Restricting clozapine use: the impact of stringent eligibility criteria. Psychiatric Services 1995;46: 801-806
4. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988;45:789-796
5. Essock SM, Hargreaves WA, Dohm FA, et al. Clozapine eligibility among state hospital patients. Schizophr Bull 1996;22:15-25
6. Revicki DA, Luce BR, Weschler JM, et al. Cost effectiveness of clozapine for treatment resistant schizophrenic patients. Hosp Community Psychiatry 1990;41:850-854
7. Frank RG. Clozapine's cost-benefits [letter with reply]. Hosp Community Psychiatry 1991;42:92
8. Goldman HH. Clozapine's cost-benefits [letter with reply]. Hosp Community Psychiatry 1991;42:92-93
9. Revicki DA, Luce BR, Weschler JA, et al. Clozapine's cost-benefits [reply to Frank and Goldman]. Hosp Community Psychiatry 1991;42:93-94
10. Davies LM, Drummond F. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 1993;162:38-42
11. Frankenburg FR, Zanarini MC, Cole JO, et al. Hospitalization rates among clozapine-treated patients: a prospective cost-benefit analysis. Ann Clin Psychiatry 1992;4:247-250
12. Reid WH, Mason M, Toprac M. Savings in hospital bed-days related to treatment with clozapine. Hosp Community Psychiatry 1994;45:261-264
13. Meltzer HY, Cola P, Way L, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993;150:1630-1638
14. Meltzer HY, Bastani B, Kwon KY, et al. A prospective study of clozapine in treatment-resistant patients, I: preliminary report. Psychopharmacology (Berl) 1989;99(suppl):S68-S72
15. Essock SM. Clozapine's cost effectiveness [letter]. Am J Psychiatry 1995; 152:152
16. Rosenheck R, Charney DS, Frisman LK, et al. Clozapine's cost effectiveness [letter]. Am J Psychiatry 1995;152:152-153
17. Schiller M, Hargreaves WA. Clozapine's cost effectiveness [letter]. Am J Psychiatry 1995;152:151-152
18. Rosenheck RA, Massari L, Frisman L. Who should receive high-cost mental health treatment and for how long? Schizophr Bull 1993;19:843-852
19. Wilson WH. Clinical review of clozapine treatment in a state hospital. Hosp Community Psychiatry 1992;43:700-703
20. Honigfeld G, Patin J. A two-year clinical end economic follow-up of patients on clozapine. Hosp Community Psychiatry 1990;41:882-885
21. Addington DE, Jones B, Bloom D, et al. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993;15:917-926
22. Bouchard R-H, Pourcher E, Chassé F, et al. Multidimensional evaluation of risperidone efficacy in an institutional setting. Presented at the International College of Neuropsychopharmacology; June 27-July 1, 1994; Washington, DC
23. Lindström E, von Knorring L, Eberhard G. Studies of selected outcome-related clinical parameters following short-term and long-term treatment with risperidone. Presented at the International College of Neuropsychopharmacology; June 27-July 1, 1994; Washington, DC
24. Thompson D. Costs of treatment with risperidone and clozapine. In: New Research Program and Abstracts of the Annual Meeting of the American Psychiatric Association; May 7, 1996; New York, NY. Abstract NR368: 168
25. Gardos G. Are antipsychotic drugs interchangeable? J Nerv Ment Dis 1974;159:343-348
26. Chouinard G, Albright P. Utility analysis of risperidone cost-effectiveness. J Clin Psychopharmacol. In press
27. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992;146: 473-481
28. Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med 1990;113:147-154
29. Plosker GL. Risperidone: does it give "enough bang for the buck"? (Report of a session at the Canadian Society of Hospital Pharmacists [Western Branches], Banff, Alberta, Canada; March 1994) INPHARMA 16 April 1994
30. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13:25-40
31. Salive ME, Mayfield JA, Weissman NW. Patient outcomes research teams and the Agency for Health Care Policy Research. Health Services Research 1990;25:697-708
32. Zarkin GA, Grabowski HG, Mauskopf J, et al. Economic evaluation of drug treatment for psychiatric disorders: the new clinical trial protocol. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:1897-1905
33. Souêtre EJ, Qing W, Hardens M. Methodological approaches to pharmacoeconomics. Fundam Clin Pharmacol 1994;8:101-106
34. Hatziandreu EJ, Brown RE, Revicki DA, et al. Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin. Pharmacoeconomics 1994;5:249-264
35. Kamlet MS, Paul N, Greenhouse J, et al. Cost utility analysis of maintenance treatment for recurrent depression. Control Clin Trials 1995;16: 17-40
36. Revicki DA, Brown RE, Palmer W, et al. Cost-effectiveness of antidepressant treatment in primary care: clinical decision analysis of nefazodone, imipramine, or fluoxetine for major depression. Pharmacoeconomics. In press
37. Torrance GW. Measurement of health utilities for economic appraisal: a review. Journal of Health Economics 1986;5:1-30
38. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989;5:559-575
39. Furlong W, Feeny D, Torrance GW, et al. Guide to Design and Development of Health-State Utility Instrumentation. Hamilton, Ontario: Centre for Health Economics and Policy Analysis, McMaster University; 1990
40. Detsky A, Naglie G. A clinician's guide to cost-effectiveness analysis. Ann Intern Med 1990;113:147-154
41. Luce BR, Elixhauser A. Standards for Socioeconomic Evaluation of Health Care Products and Services. New York, NY: Springer-Verlag; 1990
42. Rice DP. Estimating the Cost of Illness. Health Economics Series, Number 6. Rockville, Md: US Dept Health, Education and Welfare; 1966. US Dept Health, Education, and Welfare publication (PHS) 947-6
43. Alchian AA, Allen WR. University Economics. Belmont, Calif: Wadsworth Publishing; 1967
44. Weisbrod B, Test MA, Stein L. Alternative to mental hospital treatment, II: economic benefit cost analysis. Arch Gen Psychiatry 1980;37: 400-405
45. Weisbrod B A. A guide to benefit-cost analysis, as seen through a controlled experiment in treating the mentally ill. J Health Polit Policy Law 1983; 7:808-845
46. Mintz J, Mintz LI, Arruda MJ, et al. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 1992;49:761-768
47. Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al. Effects of limiting medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med 1994;331:650-655